Literature DB >> 29071281

Evaluation of VNTR polymorphisms of dopamine transporter gene and the risk of bipolar disorder in Zahedan, southeast Iran.

Mansour Shakiba1,2, Mohammad Hashemi3,4, Salah Mahdar2, Zahra Rahbari2, Gholamreza Bahari4.   

Abstract

The exact role of dopamine transporter gene (DAT1) in the pathogenesis of bipolar disorder type 1 (BD) is not understood. In the present study, we aimed to evaluate the possible association between 30, 40 and 63 bp variable number tandem repeat (VNTR) polymorphisms of DAT1 gene and the risk of type 1 (BD) in a sample of Iranian population. This case-control study was performed on 152 BD patients and 153 psychiatrically healthy subjects. Genotyping of the variant was done by polymerase chain reaction method. Totally, the findings did not support an association between DAT1 VNTR polymorphisms and the risk of BD in a sample of southeast Iranian population.

Entities:  

Keywords:  Bipolar disorder; DAT1; VNTR; dopamine transporter; polymorphism

Year:  2017        PMID: 29071281      PMCID: PMC5640894          DOI: 10.22099/mbrc.2017.25056.1261

Source DB:  PubMed          Journal:  Mol Biol Res Commun        ISSN: 2322-181X


INTRODUCTION

Bipolar disorder (BD), is an impairing mood disorder that affects about 1% of the population which is characterized by recurrent episodes of hypomania or mania and depression [1]. The dopamine transporter (DAT) is a presynaptic plasma membrane protein and responsible for reuptake of the dopamine from the synaptic cleft [2]. It is encoded by the (solute carrier family 6 (neurotransmitter transporter), member 3) gene (OMIM:126455, SLC6A3) which mapped to chromosome 5 (5p15.3) and show variable number tandem repeat (VNTR) polymorphisms [3]. It has been shown that polymorphisms of DAT1 (OMIM:126455) may play a role in predisposition to BD disorder [4-7]. In the present study, we aimed to evaluate the impact of 30, 40 and 63 bp VNTR polymorphisms of DAT1 on type 1 (BD) in a sample of Iranian population.

MATERIALS AND METHODS

This case-control study was performed on 152 confirmed patients with bipolar disorder type 1 (BD) and 153 healthy subjects. The patients were selected from BD admitted to a university-affiliated hospital (Baharan Psychiatric Hospital, Zahedan, Iran). BD was diagnosed according to DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) criteria. The controls were unrelated healthy subjects with no clinical symptoms or family histories of BD belonged to same ethnicity as patients and living in the same area as the patients (Southeast Iran). The project was approved by Ethics Committee of the Zahedan University of Medical Sciences and informed consent was taken from all subjects. DNA was extracted from whole blood samples using salting out method. Genotyping of the 30 bp (rs3836790), 40 bp (rs28363170) and 63 bp VNTR polymorphisms of DAT1 was done by polymerase chain reaction (PCR) method [8-10]. Statistical analysis was done by statistical package SPSS 22 software. Data were analyzed by independent sample t-test or χ2 test according to the data. A p-value less than 0.05 were considered statistically significant.

RESULTS AND DISCUSSION

A total of 305 subjects including 152 confirmed patients with BD1 (110 males, 42 females, mean age 35.0±10.9) and 153 unrelated healthy subjects (108 males, 45 females, mean age 34.1±11.1) were enrolled in the study. The cases and controls were match regarding age and sex (p value=0.463 and 0.731 respectively). Table 1 shows the genotype and allele frequencies of DAT1 VNTR polymorphisms in type 1 (BD) patients and controls. The findings revealed the 30, 40 as well as 63 bp VNTR polymorphisms of DAT1 gene were not associated with the risk of BD.
Table 1

Genotype and allele frequencies of the DAT1 VNTR polymorphism in bipolar disorder and healthy subjects

VNTR polymorphisms Cases n (%) Control n (%)
30-bp VNTR
5R/5R92 (60.5)80 (52.2)
5R/6R42 (27.6)63 (41.1)
6R/6R10 (6.6)5 (3.3)
6R/11R1 (0.7)1 (0.7)
6R/12R5 (3.3)3 (2.0)
5R/13R2 (1.3)1 (0.7)
χ2=7.53, df=5, p=0.183
Alleles
5R228 (75.0)224 (73.2)
6R68 (22.4)77 (25.2)
11R1 (0.3)1 (0.3)
12R5 (1.6)3 (1.0)
13R2 (0.7)1 (0.3)
χ2=1.42, df=4, p=0.840
40-bp VNTR
11R/11R76 (50.0)82 (53.6)
11R/10R64 (42.1)65 (42.4)
10R/10R9 (5.9)4 (2.6)
11R/6R3 (2.0)1 (0.7)
11R/16R0 (0.0)1 (0.7)
χ2=4.15, df=4, p=0.385
Alleles
11219 (72.1)231 (75.5)
1082 (27.0)73 (23.9)
63 (0.9)1 (0.3)
160 (0.0)1 (0.3)
χ2=2.83, df=3, p=0.417
63-bp VNTR
7R/7R76 (50.0)72 (47.1)
7R/8R59 (38.8)65 (42.5)
8R/8R17 (11.2)16 (10.4)
χ2=2.56, df=2, p=0.633
Alleles
7R211 (69.4)209 (68.3)
8R93 (30.6)97 (34.7)
χ2=0.087, df=1, p=0.295
It has been proposed that dopaminergic dysfunction contribute to the etiology of mood disorders. Dopamine is a vital neurotransmitter essential for normal brain development and function. The DAT1 is important for active reuptake of dopamine released into the synaptic cleft and ends dopamine neurotransmission. Several studies have investigated the impact of DAT1 gene polymorphisms on BD [4, 5, 7, 11-14], however, the findings were inconsistent. In summary, the findings of the present study did not support an association between 30, 40 and 63 bp VNTR polymorphisms of DAT1 gene and the risk of bipolar disorders in a sample of Iranian population. Further studies with larger sample sizes and different ethnicities are required to verify our findings. Genotype and allele frequencies of the DAT1 VNTR polymorphism in bipolar disorder and healthy subjects
  14 in total

1.  Association between 5HTT, DAT1, and DRD4 and bipolar disorder in youth.

Authors:  Victoria E Cosgrove; David J Miklowitz; Soo Hyun Rhee; Christopher Hawkey; Robin Corley; Brett Haberstick; Andrew Smolen
Journal:  Psychiatr Genet       Date:  2012-12       Impact factor: 2.458

Review 2.  Clinical practice. Bipolar disorder--a focus on depression.

Authors:  Mark A Frye
Journal:  N Engl J Med       Date:  2011-01-06       Impact factor: 91.245

3.  Family-based association studies of bipolar disorder with candidate genes involved in dopamine neurotransmission: DBH, DAT1, COMT, DRD2, DRD3 and DRD5.

Authors:  G Kirov; I Jones; F McCandless; N Craddock; M J Owen
Journal:  Mol Psychiatry       Date:  1999-11       Impact factor: 15.992

Review 4.  The dopamine transporter: role in neurotoxicity and human disease.

Authors:  Michael J Bannon
Journal:  Toxicol Appl Pharmacol       Date:  2005-05-01       Impact factor: 4.219

5.  Global variation of a 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene (SLC6A3).

Authors:  A M Kang; M A Palmatier; K K Kidd
Journal:  Biol Psychiatry       Date:  1999-07-15       Impact factor: 13.382

6.  Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension.

Authors:  Won-Tae Kim; Se-Ra Lee; Yun-Gil Roh; Seung Il Kim; Yung Hyun Choi; Mi-Hye Mun; Mi-So Jeong; Sang Seok Koh; Sun-Hee Leem
Journal:  DNA Cell Biol       Date:  2017-01-05       Impact factor: 3.311

7.  Dopamine transporter gene may be associated with bipolar disorder and its personality traits.

Authors:  Chang-Chih Huang; Ru-Band Lu; Che-Hung Yen; Yi-Wei Yeh; Han-Wei Chou; Shin-Chang Kuo; Chun-Yen Chen; Chuan-Chia Chang; Hsin-An Chang; Pei-Shen Ho; Chih-Sung Liang; Serena Cheng; Mei-Chen Shih; San-Yuan Huang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-12-30       Impact factor: 5.270

8.  Possible locus for bipolar disorder near the dopamine transporter on chromosome 5.

Authors:  J R Kelsoe; A D Sadovnick; H Kristbjarnarson; P Bergesch; Z Mroczkowski-Parker; M Drennan; M H Rapaport; P Flodman; M A Spence; R A Remick
Journal:  Am J Med Genet       Date:  1996-11-22

9.  Association of dopamine transporter gene variants with childhood ADHD features in bipolar disorder.

Authors:  Tiffany A Greenwood; Eun-Jeong Joo; Tatyana Shekhtman; A Dessa Sadovnick; Ronald A Remick; Paul E Keck; Susan L McElroy; John R Kelsoe
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-12-19       Impact factor: 3.568

10.  Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR.

Authors:  D J Vandenbergh; A M Persico; A L Hawkins; C A Griffin; X Li; E W Jabs; G R Uhl
Journal:  Genomics       Date:  1992-12       Impact factor: 5.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.